Test Price
2,800 AED✅ Home Collection Available
TDRD7 Gene Cataract, Autosomal Recessive Congenital Type 4 Genetic Test in UAE | 2,800 AED | DHA-Approved
Executive Summary & Core Metrics
🎯 Diagnostic Accuracy: 99.9% Analytical Sensitivity via ISO 9001:2015 Certified NGS Processing
🚑 Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM to 11 PM)
📞 Clinical Guidance: Telephonic Post-Test Clinical Interpretation by DHA-Licensed Specialists
💳 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
The TDRD7 genetic test provides definitive molecular diagnosis for autosomal recessive congenital cataract type 4 (ARCC4) using advanced next-generation sequencing, enabling precise family planning, carrier screening, and early surgical intervention.
Test Overview & Methodology
The TDRD7 Genetic Test identifies pathogenic variants in the TDRD7 gene responsible for autosomal recessive congenital cataract type 4 (ARCC4), a severe infantile lens opacity that can lead to amblyopia and lifelong visual impairment if untreated. This UAE-based next-generation sequencing assay delivers a 99.9% analytical sensitivity with results in 3–4 weeks, fully compliant with DHA Genetic Testing regulations and ISO 9001:2015, providing definitive molecular diagnosis, carrier screening, and informed family planning.
| Feature | Our NGS Test | Alternative (Sanger / Karyotyping) |
|---|---|---|
| Mutation Coverage | Entire TDRD7 gene – all exons & splice sites | Single-exon hot-spot or structural changes only |
| Analytical Sensitivity | >99.9% (confirmed by spiked-in controls) | ~95% for point mutations; misses indels |
| Turnaround Time | 3–4 weeks | 4–8 weeks (often multi-step) |
| Methodology | NGS (Illumina NovaSeq 6000) + IGV variant calling | PCR + Sanger / G-banding |
| VUS Resolution | Comprehensive bioinformatics + ACMG classification | Limited; often requires additional testing |
| Clinical Relevance | Direct correlation with congenital cataract phenotype | May miss splice/del mutations |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I work closely with families confronting a potential diagnosis of congenital cataract. This NGS test delivers the molecular precision needed to guide surgical timing, genetic counselling, and surveillance for associated syndromes. A positive result is not a sentence but a starting point for proactive eye care. Always correlate genetic findings with a detailed ophthalmic examination and a three-generation pedigree analysis.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Treatment Precautions
⚠️ Critical Medication Advisory
Do not pause, alter, or discontinue any prescribed therapy — particularly corticosteroids, immunosuppressants, or anti-epileptic agents — without direct consultation with your treating physician. This genetic test does not evaluate pharmacologic interactions; abrupt cessation may provoke severe metabolic, endocrine, or neurological complications. Always discuss medication adjustments with your doctor prior to sample collection.
Exclusion Criteria & Emergency Indicators
- Exclusion Criteria: Unsuitable if blood/DNA sample is hemolysed, clotted, or drawn from a donor within 24 hours after blood transfusion; samples with suspected bacterial overgrowth or visible contamination will be rejected. Patients unable to provide age-appropriate informed consent require parental or legal guardian authorization per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If the child develops sudden eye redness, photophobia, leukocoria with pain, or corneal clouding after sample collection, seek immediate ophthalmic emergency care. Do not wait for test results.
Patient FAQ & Clinical Guidance
1. What exactly does the TDRD7 gene test detect?
This next-generation sequencing test reads the entire TDRD7 gene to identify disease-causing mutations responsible for congenital cataract type 4, delivering a definitive molecular diagnosis and carrier status. It detects single nucleotide variants, small insertions/deletions, and copy-number changes down to exon level. The result enables accurate genetic counselling and guides early surgical intervention.
2. How is the sample collected and what preparation is needed?
Our UAE-licensed phlebotomists collect a small peripheral whole blood sample, a dried blood spot on an FTA card, or extracted DNA via temperature-controlled cold-chain transport, all from the comfort of your home. No fasting is required, but a genetic counselling session is mandatory to draw a pedigree chart and obtain informed consent. For infants, a heel-prick or venous blood draw is used. The entire process is ISO 9001:2015 compliant.
3. What is the turnaround time and total cost in the UAE?
Results are reported within 3 to 4 weeks from sample receipt, and the comprehensive test price is 2,800 AED, inclusive of pre-test counselling and post-test clinical discussion. This fee covers sample collection, sequencing, bioinformatics analysis, and final interpretation signed by a DHA-licensed molecular geneticist. Direct insurance billing can be confirmed via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
- Licensed under DHA Facility No. 1143; operates in full compliance with MOHAP genetic testing regulations.
- Strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — all genetic data encrypted at rest and in transit; no offshore storage or third-party access without explicit consent.
- Compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health records and telemedicine consultations.
- Clinical safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, mandating documented informed consent and pre-test genetic counselling for all minors.
- ISO 9001:2015 Certified (Certificate No. INT/EGQ/2509DA/3139) for consistent quality management and cold-chain integrity.
Clinical & Logistical Metadata
| Test Name | TDRD7 Gene Cataract, Autosomal Recessive Congenital Type 4 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood, Dried Blood Spot (FTA card), or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq 6000 with IGV variant calling and ACMG classification |
| ICD-10-CM Code | Q12.0 (Congenital cataract) |
| LOINC Code | 81258-2 (Genetic counseling and testing panel) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians